Should I buy Corcept Therapeutics Incorporated (CORT) stock or is it too late?

Corcept Therapeutics Incorporated · Health Care · price $117

See the full Corcept Therapeutics Incorporated (CORT) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: HC Wainwright & Co. — 61% of its targets hit on this sector (321 calls tested). It aims for $165 (+41 %), call made on July 31, 2026, maturing on July 31, 2027 (28 d ago).

The 1 reliable analyst $165+41 %

The 4 other firms $117-0.4 %

How to read it: the 1 reliable firms are not filtered by optimism — 1 aim above the price, 0 below, hence their $165 median. “The 4 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Corcept Therapeutics Incorporated

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Truist Securities	88 %	+104.2 %	8	$150 +28%
HC Wainwright & Co.	73 %	+39.8 %	22	$165 +41%
Piper Sandler	70 %	+29.4 %	10	$165 +41%
Canaccord Genuity	78 %	+27.6 %	9	$161 +38%

In short — Should you invest in Corcept Therapeutics Incorporated? Is it too late, still worth it? Analysts are overwhelmingly positive (80% buy, median target $161, i.e. +38%), and the most reliable on CORT targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

80% of analysts rate it a buy (Buy consensus, 5 ratings) — a sign of market conviction.
Median price target $161, i.e. +38% from the current price ($117).
The most reliable firm on CORT, Canaccord Genuity (78% hit rate, 9 scored calls), targets $161 (call made on July 30, 2026, maturing on July 30, 2027) (+38%) in its most recent call, and $140 (call made on September 10, 2025, maturing on September 10, 2026) (+20%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 5 ratings, 1 is a sell.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on CORT

Median target $161 (+38%) · 5 ratings · Buy consensus

Strong Buy00%

Buy480%

Hold00%

Sell120%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Corcept Therapeutics Incorporated now?

We won't decide for you. The facts: 80% of analysts rate it a buy, median target $161 (+38%), and Canaccord Genuity (most reliable on CORT, 78%) targets $161. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Corcept Therapeutics Incorporated?

Not according to analysts: the median target ($161) is still +38% above the current price ($117) (most reliable on CORT: Canaccord Genuity, 78%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Corcept Therapeutics Incorporated still worth investing in?

It depends on the gap between the price ($117) and its estimated value: analysts target $161 on median (+38%), with 80% buys (most reliable on CORT: Canaccord Genuity, 78%). Cross-check with their real reliability on CORT and the cautions above. Information, not advice.

What's the main risk in buying CORT?

The consensus is not unanimous: of 5 ratings, 1 is a sell.

→ Go deeper: the full Corcept Therapeutics Incorporated profile (consensus, analyst reliability, price target, performance).